ESMO





“This is truly a practice-changing study, not just for our patients but for the design of other studies. We can successfully identify candidates for olaparib. We saw a clinically meaningful improvement in outcomes for patients with HRR genetic alterations, driven mainly by BRCA2,” said Eleni Efstathiou, MD, PhD. Read More ›

Postsurgery Observation Better Than Radiotherapy in Men with Prostate Cancer

Barcelona, Spain—Results of the new clinical trial RADICALS-RT indicate that using salvage radiotherapy immediately after surgery leads to equivalent outcomes in terms of progression-free survival (PFS) versus adjuvant radiotherapy in men with prostate cancer undergoing radical prostatectomy. These late-breaking results were presented at the ESMO Congress 2019 by lead investigator Chris Parker, MD, FRCR, MRCP, Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, England.

Read More ›

Barcelona, Spain—Late-breaking data from 2 clinical trials presented at ESMO 2019 will likely change the treatment paradigm for pre- or postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer, regardless of menopausal status. The MONALEESA-3 study and the MONARCH-2 study showed an improved overall survival (OS) with the addition of the CDK4/6 inhibitor ribociclib (Kisqali) or abemaciclib (Verzenio) to endocrine therapy as first- or second-line therapy. The results were presented at the Presidential Session of the meeting. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early. Read More ›

Page 1 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: